Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Canaccord Genuity lowers target price on System1

(Sharecast News) - Analysts at Canaccord Genuity lowered marketing research firm System1 from 'buy' to 'speculative buy' on Tuesday and cut their target price on the stock from 865p to 550p, stating that macro headwinds appear to have paused growth. System1 released an unscheduled trading update ahead of its interim results, guiding to more challenging trading conditions, with several larger customers spending "lower and slower" in the context of uncertain macro conditions. FX headwinds were also a drag on the top-line.

As such, Q2 trading was said to have followed Q1's subdued activity, with interim revenues guided to be 5% lower than the prior year, which Canaccord Genuity estimates to be £17.4m. FY26 revenue was now anticipated to be broadly flat year-on-year.

However, on a more positive note, Canaccord Genuity noted that System1 has continued to win new logos, including a number of competitive wins, with new business revenue expected to be similar to last year. Within this, Innovation was reported to have seen good demand, albeit from a smaller base.

"Nevertheless, given the persistent macro uncertainties and limited forward visibility, with H1 sales guidance implying a H2 weighting to both revenue and likely earnings (covering 47% of our updated FY26E sales estimate), we update our recommendation to a 'spec buy' (from 'buy')," said the Canadian bank. "We expect cash to hold strong throughout the forecast period as management keeps a tight control on costs, providing sufficient firepower to fund the dividend - as such, we model the dividend payout at the higher end of management's 30-40% payout range in both years."

On its revised estimates, Canaccord said System1 trades on a 2026 calendar year enterprise value-to-sales ratio of 1.0x and EV/EBIT ratio of 15x.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.